The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -19.09%.However, over the last six months, we can see a weaker performance of 103.24%. Over the last 30 days, the price of TGTX has leaped by -8.17%. And in the last five days, it has fallen by -6.05%.
TG Therapeutics Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $35.67 on 05/04/23 and the lowest value was $6.46 on 10/16/23.
52-week price history of TGTX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. TG Therapeutics Inc’s current trading price is -61.26% away from its 52-week high, while its distance from the 52-week low is 113.93%. The stock’s price range during this period has varied between$6.46 and $35.67. The TG Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 3.06 million for the day, a figure considerably lower than their average daily volume of 3.57 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
TG Therapeutics Inc (TGTX) has experienced a quarterly decline of -9.67% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.13B and boasts a workforce of 264 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 15.68, with a change in price of +1.50. Similarly, TG Therapeutics Inc recorded 4,398,989 in trading volume during the last 100 days, posting a change of +12.18%.
TGTX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for TGTX stands at 0.69. Similarly, the long-term debt-to-equity ratio is also 0.68.
TGTX Stock Stochastic Average
TG Therapeutics Inc’s raw stochastic average for the past 50 days is presently 15.86%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 11.07%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 9.78% and 12.92%, respectively.
